Pathology Considerations in Patients Treated with Neoadjuvant Chemotherapy

Sunati Sahoo, Susan C. Lester

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Neoadjuvant therapy (NAT) originally reserved for the treatment of inflammatory and locally advanced breast cancers is currently offered to women with earlier-stage and operable breast carcinoma. NAT allows more women to be eligible for breast conservation surgery and provides an opportunity to assess the response of carcinomas to therapy. This review focuses on the predictors of therapeutic response in pretreatment tumor, evaluation of post-treatment breast and lymph node specimens and classification systems to evaluate degree of response to NAT.

Original languageEnglish (US)
Pages (from-to)749-774
Number of pages26
JournalSurgical Pathology Clinics
Issue number3
StatePublished - Sep 2012


  • Breast cancer
  • Histology
  • NAT
  • Neoadjuvant therapy
  • Pathologic diagnosis
  • Preoperative therapy
  • Tumor markers

ASJC Scopus subject areas

  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Pathology Considerations in Patients Treated with Neoadjuvant Chemotherapy'. Together they form a unique fingerprint.

Cite this